SciELO - Scientific Electronic Library Online

 
vol.27 número10Duloxetina y otros antidepresivos tricíclicos: efectos farmacodinámicos en el tracto urinario inferiorSensibilidad microbiana de escherichia coli en infecciones urinarias extrahospitalarias índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

Compartilhar


Actas Urológicas Españolas

versão impressa ISSN 0210-4806

Resumo

RODRIGUEZ CORDON, M.; FERRER ALBIACH, E.  e  FERRER ALBIACH, C.. Current multiapproach treatment of metastatic prostate cancer. Actas Urol Esp [online]. 2003, vol.27, n.10, pp.767-782. ISSN 0210-4806.

Prostate cancer is one of the commonest causes of cancer-related death in the western world. The morbi-mortality associated is usually a direct consequence of metastatic spread to bone, in up to 50% of patients at first presentation. The aim of treatment of metastatic patients is to alleviate and to prevent the distressing symptoms. The approach include hormone-therapy, radiotherapy, radionuclides, surgery, chemotherapy, bisphosphonates and new drugs (agents that inhibit angiogenesis, inmmunotherapy and therapies that affect the differentiation). Decisions about therapy must also take into consideration the androgen-dependent or independent, so hormone-therapy is the first step of the treatment; the number and location of bone metastases; the severity of symptoms; the available of therapies; the status performance of patient; the prognosis and the cost-effect relationship. Some treatments have established indications whereas others are still in process of study in order to determinate their efficacy, their model of treatment and their indications. This article revises and updates these treatments.

Palavras-chave : Prostate; Metastatic; Hormone-therapy; Radiotherapy; Chemotherapy; Bisphosphonates; Radionuclides; Surgery; New approaches.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons